Completed PHASE1 INTERVENTIONAL 1-arm NCT06846099

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

A Phase I/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of Pl3Kα-Selective Inhibitor RP903 (JS105) in Subjects With Advanced Malignancies

Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd.

Conditions Breast Cancer Cervical Cancer Endometrial Cancer Ovarian Cancer Solid Tumor Cancer

Interventions RP903

Updated 2 times since 2025 Last updated: Dec 16, 2025 Started: Dec 7, 2022 Primary completion: May 30, 2025 Completion: May 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Breast Cancer and Cervical Cancer and is currently completed. Risen (Suzhou) Pharma Tech Co., Ltd. leads this study, which shows 2 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1

Status: Recruiting → Completed
Mar 2025 — Jan 2026 [monthly]

Recruiting PHASE1

First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Risen (Suzhou) Pharma Tech Co., Ltd.

Data source: Risen (Suzhou) Pharma Tech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Bengbu, China , Changchun, China , Chengdu, China , Chongqing, China , Fuzhou, China , Hangzhou, China , Harbin, China , Jinan, China , Jining, China and 10 more locations